Fasciculations from a cholinesterase inhibitor
Objective: Present and discuss fasciculations in the setting of acetylcholinesterase inhibitors. Background: Specific acetylcholinesterase (AChE) inhibitors (e.g., donepezil, rivastigmine, galantamine) are the current first-line treatment…Intranasal Delivery of Bromocriptine loaded Lipid Nano Carriers for Enhanced Brain Delivery in Parkinson’s disease
Objective: The objective of this research work is to develop a lipid nanocarrier system of Bromocriptine and evaluate its increased efficacy in the management of…Application of a Qualitative Model to Elucidate the Role of the Alpha-Synuclein System in Parkinson’s Disease.
Objective: Objective: In order to improve the understanding of the alpha-synuclein system and its role in Parkinson’s disease, Elan and Rosa collaborated in the development…Parkinson’s Disease Medications Availability in Each Philippine Region
Objective: This study aimed to enumerate the different Parkinson’s disease medications in the Philippines and describe the distribution and availability among the 17 regions of…Determinant factors of treatment adherence in Parkinson’s disease
Objective: To determine factors predicting treatment adherence in patients with idiopathic Parkinson’s disease. Background: Parkinson’s disease is the second most common cause of neurodegenerative disease…Intrajejunal levodopa infusion (ILI) for Parkinson’s Disease (PD): A Canadian Experience
Objective: To review the benefits and complications of ILI for PD in a tertiary movement disorders center in Canada. Background: ILI has been in use…Clinical Experience with Initiation of Carbidopa/Levodopa Enteral Suspension in Parkinson’s Disease Patients with Cognitive Impairment
Objective: To assess the safety and efficacy of carbidopa/levodopa enteral suspension (CLES) in Parkinson’s disease (PD) patients with cognitive impairment. Background: As Parkinson’s Disease progresses,…Three-year follow-up of high-dose ubiquinol supplementation in a case of familial multiple system atrophy with compound heterozygous COQ2 mutations
Objective: To present the detailed clinical features of a patient with familial MSA carrying compound heterozygous COQ2 mutations and report the outcome of a high-dose ubiquinol…The highly-selective mGluR2 positive allosteric modulator LY-487,379 alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To determine the effectiveness of highly-selective metabotropic glutamate 2 receptor (mGluR2) activation at alleviating and preventing the development of L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia. Background: Chronic…Speech and voice response to levodopa in late-stage Parkinson’s Disease patients: report from an acute levodopa challenge
Objective: to assess the change of speech and voice after an acute L-dopa challenge in late-stage Parkinson’s disease (LSPD). Background: PD patients are classically affected…
- « Previous Page
- 1
- …
- 27
- 28
- 29
- 30
- 31
- …
- 34
- Next Page »